New Product Offerings, Development and Research Collaboration, Upcoming Investor Conference, and Board Election - Analyst Notes on CVS Caremark, Teva, Zoetis, McKesson, and Mylan

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 24, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding CVS Caremark Corporation (NYSE: CVS), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Zoetis, Inc. (NYSE: ZTS), McKesson Corporation (NYSE: MCK), and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

CVS  Caremark  Corporation  Analyst  Notes

On March 18, 2014, CVS Caremark Corporation (CVS Caremark) announced that its retail division CVS/pharmacy is now providing ScripTalk talking prescription labels for prescriptions ordered for home delivery through the Company's online pharmacy - CVS.com - available to the blind or visually impaired. The Company noted that ScripTalk is collaboration between CVS/pharmacy, the American Foundation for the Blind, American Council of the Blind, and California Council of the Blind. "The California Council of the Blind applauds CVS's willingness to offer access to the information on prescription medication labels. As a result of this initiative, persons who are blind or visually impaired who use CVS mail order to fill their prescription needs will have the same direct, and independent access to label information as do sighted customers," said Donna Pomerantz, President of California Council of the Blind. The full analyst notes on CVS Caremark Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03242014/CVS/report.pdf

--

Teva  Pharmaceutical  Industries  Ltd.  Analyst  Notes

On March 13, 2014, Teva Pharmaceutical Industries Ltd. (Teva) announced collaboration with the UK Government's National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI). The Company informed that the two-part collaboration, Clinical Drug Development Collaboration and Dementia Research Collaboration, follows the creation of an important new research infrastructure model by the UK's National Health Service (NHS). "We are delighted to collaborate with NIHR on both clinical development and early dementia research. It will be a catalyst for innovation to take place within a healthcare system that is admired the world over," said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva. "The relationship between Teva, Israel and the UK is a long and fruitful one and I am proud that we can now add another example of us working together as partners for innovation and health." The full analyst notes on Teva Pharmaceutical Industries Ltd. are available to download free of charge at:

http://www.AnalystsReview.com/03242014/TEVA/report.pdf

--

Zoetis,  Inc.  Analyst  Notes

On March 13, 2014, Zoetis, Inc. (Zoetis) announced that it will participate in the Jefferies Animal Health Summit. The Company's CEO Juan Ramón Alaix is scheduled to present on March 27, 2014, at 9:30 a.m.ET at the Jefferies Conference Center in New York, NY. The full analyst notes on Zoetis, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03242014/ZTS/report.pdf

--

McKesson  Corporation  Analyst  Notes

On March 5, 2014, McKesson Corporation (McKesson) announced that its Board of Directors has elected N. Anthony Coles, M.D., as a new independent director, effective April 29, 2014. Further, the Company informed that Dr. Coles has also been appointed as a member of the Board's Compensation Committee as well as the Finance Committee. His term as a director will expire at McKesson's 2014 Annual Meeting of Stockholders unless he is nominated again as a director, and elected by stockholders at the meeting. The full analyst notes on McKesson Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03242014/MCK/report.pdf

--

Mylan,  Inc.  Analyst  Notes

On March 11, 2014, Mylan, Inc. (Mylan) announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. The Company noted that the product was determined to be bioequivalent and therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL of Hospira Inc. Mylan further confirmed that the product's Abbreviated New Drug Application (ANDA) has received final approval from the FDA. The full analyst notes on Mylan, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03242014/MYL/report.pdf

--


About  Analysts  Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR  NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE  PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT  FINANCIAL  ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO  WARRANTY  OR  LIABILITY  ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.